Compare Stocks → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BLPHNASDAQ:CLSNNASDAQ:GNPXNASDAQ:MNPRNASDAQ:ONCY Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLPHBellerophon Therapeutics$0.05$0.05$0.03▼$11.15$662K0.6761,081 shs47,040 shsCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsGNPXGenprex$2.21-4.3%$3.46$2.09▼$42.40$4.22M-0.6172,263 shs19,535 shsMNPRMonopar Therapeutics$0.66+1.5%$0.75$0.27▼$1.75$11.47M1.194.33 million shs39,446 shsONCYOncolytics Biotech$1.06$1.07$0.88▼$3.39$79.95M1.93369,956 shs61,862 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLPHBellerophon Therapeutics-7.68%-0.73%-9.68%-6.72%-99.25%CLSNImunon0.00%0.00%0.00%0.00%0.00%GNPXGenprex-4.33%0.00%-26.33%-75.75%-93.24%MNPRMonopar Therapeutics+1.08%+1.08%-7.46%+77.57%-40.81%ONCYOncolytics Biotech0.00%+1.92%+2.91%-15.20%-6.19%The "Smart Money" Is Ready for May 1st Are You? (Ad)Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLPHBellerophon Therapeutics2.1088 of 5 stars3.00.00.04.83.20.00.6CLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AGNPXGenprex4.2603 of 5 stars3.55.00.04.70.60.81.3MNPRMonopar Therapeutics2.1833 of 5 stars3.55.00.00.00.01.70.6ONCYOncolytics Biotech0.8071 of 5 stars3.53.00.00.00.60.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLPHBellerophon Therapeutics2.00Hold$2.003,596.86% UpsideCLSNImunonN/AN/AN/AN/AGNPXGenprex3.00Buy$10.00352.49% UpsideMNPRMonopar Therapeutics3.00Buy$2.00204.41% UpsideONCYOncolytics Biotech3.00Buy$4.00277.36% UpsideCurrent Analyst RatingsLatest ONCY, BLPH, CLSN, GNPX, and MNPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024MNPRMonopar TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$2.004/4/2024ONCYOncolytics BiotechRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$3.004/3/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/25/2024GNPXGenprexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$10.002/14/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLPHBellerophon Therapeutics$5.64M0.12N/AN/A$0.27 per share0.20CLSNImunon$500K0.00N/AN/A$9.66 per share0.00GNPXGenprexN/AN/AN/AN/A$4.99 per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$0.38 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A$0.27 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%5/13/2024 (Estimated)CLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AGNPXGenprex-$30.86M-$24.80N/AN/AN/AN/A-245.62%-185.50%5/27/2024 (Estimated)MNPRMonopar Therapeutics-$8.40M-$0.61N/AN/AN/AN/A-115.79%-88.05%5/9/2024 (Estimated)ONCYOncolytics Biotech-$20.56M-$0.30N/AN/AN/AN/A-105.97%-72.80%5/3/2024 (Estimated)Latest ONCY, BLPH, CLSN, GNPX, and MNPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023MNPRMonopar Therapeutics-$0.17-$0.12+$0.05-$0.12N/AN/A3/7/2024Q4 2023ONCYOncolytics Biotech-$0.11-$0.04+$0.07-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLPHBellerophon TherapeuticsN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLPHBellerophon TherapeuticsN/A3.963.96CLSNImunon0.136.526.52GNPXGenprexN/A2.312.31MNPRMonopar TherapeuticsN/A4.174.17ONCYOncolytics BiotechN/A9.019.01OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLPHBellerophon Therapeutics10.61%CLSNImunon12.97%GNPXGenprex14.05%MNPRMonopar Therapeutics1.83%ONCYOncolytics Biotech6.82%Insider OwnershipCompanyInsider OwnershipBLPHBellerophon Therapeutics5.20%CLSNImunon4.66%GNPXGenprex11.54%MNPRMonopar Therapeutics41.60%ONCYOncolytics Biotech0.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionNo DataCLSNImunon277.10 million6.77 millionOptionableGNPXGenprex261.91 million1.69 millionOptionableMNPRMonopar Therapeutics1117.45 million10.19 millionNot OptionableONCYOncolytics Biotech2975.42 million75.35 millionNot OptionableONCY, BLPH, CLSN, GNPX, and MNPR HeadlinesSourceHeadlineClosing Bell: Oncolytics Bio up on Friday (ONC)theglobeandmail.com - April 21 at 5:51 PMBiotech Breakthroughs Spearhead Fight Against Rising Breast Cancer Casestheglobeandmail.com - April 13 at 12:42 AMUSA News Group: Biotech Innovations Paving the Way in Breast Cancer Fightfinanznachrichten.de - April 11 at 2:15 PMOncolytics seeking FDA meeting to discuss registration-enabling studymsn.com - April 11 at 2:15 PMOncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDAprnewswire.com - April 11 at 7:00 AMOncolytics Biotech (NASDAQ:ONCY) Now Covered by Analysts at Raymond Jamesmarketbeat.com - April 4 at 2:58 PMUSA News Group: Biotech's Role in Addressing the Pancreatic Cancer Emergencyfinanznachrichten.de - March 14 at 9:24 AMBuy Rating Affirmed for Oncolytics Biotech Amidst Promising Pipeline and Advancements in Cancer Treatment Trialsmarkets.businessinsider.com - March 11 at 7:59 AMOncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 10 at 10:18 AMBuy Rating Affirmed on Oncolytics Biotech Amid Progress and Strategic Clinical Trialsmarkets.businessinsider.com - March 8 at 8:46 PMOncolytics Biotech Inc.: Oncolytics Biotech Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlightsfinanznachrichten.de - March 8 at 10:45 AMOncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlightsprnewswire.com - March 7 at 4:01 PMOncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCANprnewswire.com - March 5 at 7:00 AMOncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conferenceprnewswire.com - February 28 at 7:00 AMHere's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situationfinance.yahoo.com - February 15 at 3:44 PMOncolytics Biotech Incbaystreet.ca - February 15 at 10:44 AMCancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatmentsnewsfilecorp.com - February 15 at 8:00 AMOncolytics Biotech Inc.: Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortfinanznachrichten.de - February 14 at 1:27 PMOncolytics Biotech® Inc.: Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortfinanznachrichten.de - February 14 at 8:27 AMOncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortfinance.yahoo.com - February 14 at 8:27 AMOncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohortprnewswire.com - February 14 at 7:00 AMOutlook stock rallies on private placement, FDA study agreementmsn.com - January 23 at 11:32 AMOncolytics Biotech® Inc.: Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directorsfinanznachrichten.de - January 9 at 7:50 AMOncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directorsfinance.yahoo.com - January 9 at 7:50 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.ImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.GenprexNASDAQ:GNPXGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Monopar TherapeuticsNASDAQ:MNPRMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Oncolytics BiotechNASDAQ:ONCYOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.